TMO vs TXG
TMO: A massive, diversified life sciences conglomerate providing the essential infrastructure, tools, and services that enable scientific research and global healthcare diagnostics. TXG: 10x Genomics provides advanced single-cell and spatial biology platforms that empower researchers to decode complex biological systems at high resolution.
Side-by-side fundamentals
| Metric | TMO | TXG | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $651.98 | $77.28 | |
| Market cap | $241.1B | $9.9B | |
| P/E as of 2026-10-08 | 35.10 | n/a | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | 169.13 | n/a | |
| Net margin FY2025, SEC XBRL | +15.0% | -6.8% | TMO higher |
| Gross margin FY2025, SEC XBRL | n/a | +69.1% | |
| Operating margin FY2025, SEC XBRL | +17.4% | -9.5% | TMO higher |
| ROE FY2025, SEC XBRL | +12.6% | -5.5% | TMO higher |
| ROA FY2025, SEC XBRL | +6.1% | -4.2% | TMO higher |
| Debt / equity as of 2026-09-02 | 0.81 | 0.00 | TXG lower |
| Revenue growth (YoY) as of 2026-09-02 | +7.2% | -4.3% | TMO higher |
| Revenue CAGR (3y) SEC XBRL | -0.3% | +7.6% | TXG higher |
| Dividend yield as of 2026-09-02 | +0.3% | n/a | |
| Dividend streak (yrs) SEC XBRL | 14 | 0 | TMO higher |
| Beta as of 2026-09-02 | 0.77 | 1.92 | |
| 1-year return as of 2026-10-08 close | +21.6% | +540.3% | TXG higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.